Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

AKLI

Akili (AKLI)

Akili Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AKLI
FechaHoraFuenteTítuloSímboloCompañía
14/05/202415:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKLIAkili Inc
14/05/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKLIAkili Inc
14/05/202415:01Business WireAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
06/05/202416:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
30/04/202407:00Business WireAkili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsNASDAQ:AKLIAkili Inc
06/03/202415:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AKLIAkili Inc
06/03/202415:11Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AKLIAkili Inc
06/03/202415:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKLIAkili Inc
29/02/202415:01Business WireAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
27/02/202401:00Business WirePureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
26/02/202407:47Business WireAkili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in JapanNASDAQ:AKLIAkili Inc
23/02/202416:28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKLIAkili Inc
23/02/202406:57Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AKLIAkili Inc
21/02/202415:05Business WireAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesNASDAQ:AKLIAkili Inc
18/12/202307:00Business WireEndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17NASDAQ:AKLIAkili Inc
09/11/202315:02Business WireAkili Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
19/10/202311:27Business WireAkili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ETNASDAQ:AKLIAkili Inc
12/10/202307:00Business WireEmployees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study FindsNASDAQ:AKLIAkili Inc
06/10/202306:00Business WireAkili Announces Leadership TransitionNASDAQ:AKLIAkili Inc
27/09/202306:45Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKLIAkili Inc
21/09/202307:00Business WireAkili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHDNASDAQ:AKLIAkili Inc
13/09/202307:11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKLIAkili Inc
13/09/202307:00Business WireAkili Announces Business Transformation, Focusing on Non-prescription ModelNASDAQ:AKLIAkili Inc
10/08/202315:01Business WireAkili Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
10/07/202306:00Business WireAkili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ETNASDAQ:AKLIAkili Inc
07/06/202306:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AKLIAkili Inc
07/06/202306:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AKLIAkili Inc
07/06/202306:00Business WireAkili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHDNASDAQ:AKLIAkili Inc
31/05/202306:00Business WireAkili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych CongressNASDAQ:AKLIAkili Inc
11/05/202315:01Business WireAkili Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKLIAkili Inc
 Showing the most relevant articles for your search:NASDAQ:AKLI

Su Consulta Reciente